Key Points
- Director Ann Rhoads sold 5,000 shares for $425,000, reducing her holdings by 12.38% to 35,384 shares.
- Globus Medical’s quarterly EPS of $1.23 beat estimates of $1.20, but revenue of $763.7 million fell short of forecasts and declined 0.7% year over year. Full-year EPS guidance is $4.95–$5.05, while revenue guidance also trails consensus.
- Analysts have a Moderate Buy consensus rating on GMED, with an average price target of $99.46.
Globus Medical, Inc. (NYSE:GMED - Get Free Report) Director Ann Rhoads sold 5,000 shares of Globus Medical stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the sale, the director directly owned 35,384 shares of the company's stock, valued at $3,007,640. This trade represents a 12.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Globus Medical Stock Performance
NYSE:GMED opened at $81.13 on Friday. The stock has a 50-day simple moving average of $77.44 and a 200-day simple moving average of $83.29. The stock has a market cap of $10.89 billion, a P/E ratio of 20.75, a P/E/G ratio of 1.40 and a beta of 0.98. Globus Medical, Inc. has a 1 year low of $60.36 and a 1 year high of $101.40.
Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, beating analysts' consensus estimates of $1.20 by $0.03. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The business had revenue of $763.72 million for the quarter, compared to the consensus estimate of $792.39 million. During the same quarter in the prior year, the business posted $1.18 EPS. The business's revenue for the quarter was down .7% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities research analysts predict that Globus Medical, Inc. will post 4.99 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts recently issued reports on GMED shares. Zacks Research raised Globus Medical from a "hold" rating to a "strong-buy" rating in a report on Monday, August 10th. BTIG Research reissued a "neutral" rating on shares of Globus Medical in a report on Friday, September 18th. Royal Bank Of Canada reduced their price objective on shares of Globus Medical from $115.00 to $85.00 and set an "outperform" rating for the company in a research report on Thursday, October 1st. Wells Fargo & Company lowered their target price on shares of Globus Medical from $103.00 to $99.00 and set an "overweight" rating for the company in a report on Friday, August 7th. Finally, UBS Group initiated coverage on shares of Globus Medical in a report on Tuesday, July 28th. They issued a "neutral" rating and a $82.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $99.46.
Check Out Our Latest Stock Analysis on GMED
Institutional Trading of Globus Medical
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its holdings in shares of Globus Medical by 4.5% in the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company's stock valued at $656,831,000 after purchasing an additional 328,217 shares during the last quarter. Sculptor Capital LP boosted its position in shares of Globus Medical by 1.9% in the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company's stock valued at $263,477,000 after purchasing an additional 58,000 shares during the period. Dimensional Fund Advisors LP grew its stake in Globus Medical by 2.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company's stock worth $152,474,000 after buying an additional 33,976 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in Globus Medical by 14.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company's stock worth $133,731,000 after buying an additional 225,534 shares during the last quarter. Finally, Boston Trust Walden Corp grew its stake in Globus Medical by 4.4% during the 3rd quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company's stock worth $123,071,000 after buying an additional 69,782 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company's stock.
Trending Headlines about Globus Medical
Here are the key news stories impacting Globus Medical this week:
- Positive Sentiment: Globus Medical reported third-quarter EPS of $1.23, topping the $1.20 consensus and rising from $1.18 a year earlier. The company also increased its share-repurchase authorization by $500 million, which could support shareholder returns. Third-quarter results and repurchase program
- Positive Sentiment: The company’s acquisition of Synaptive Medical adds cranial-neurosurgery technology and may strengthen its position in cranial procedures. Globus Medical acquires neurosurgery technology
- Neutral Sentiment: Director Ann Rhoads sold 5,000 shares for $425,000, reducing her reported holdings by 12.38%. A single insider sale does not necessarily indicate a change in the company’s outlook. SEC ownership filing
- Negative Sentiment: Quarterly revenue was $763.7 million, below analysts’ $792.4 million estimate and down 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion also trails the $3.2 billion consensus; EPS guidance of $4.95–$5.05 is broadly in line with the $5.00 estimate. The sales miss and softer revenue outlook likely outweighed the EPS beat. Quarterly results and guidance
About Globus Medical
(
Get Free Report)
Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.
Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
